BI-1622
CAT:
804-HY-150023-03
Size:
10 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
BI-1622
- CAS Number: 2681392-19-6
- UNSPSC Description: BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC50 of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile[1].
- Target Antigen: Btk; CDK; EGFR; Itk; JAK; PI4K; Raf
- Type: Reference compound
- Related Pathways: Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;MAPK/ERK Pathway;PI3K/Akt/mTOR;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
- Applications: Cancer-Kinase/protease
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/bi-1622.html
- Solubility: DMSO : 100 mg/mL (ultrasonic)
- Smiles: O=C(N1CCN(CC1)C2=NC3=C(NC4=CC=C(C(C)=C4)OC5=CC6=NC=NN6C=C5)N=CN=C3C=N2)C=C
- Molecular Weight: 508.53
- References & Citations: [1]Lamarre L, et al. Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling. Nat Cancer. 2022 Jul;3(7):821-836.
- Shipping Conditions: Room Temperature
- Clinical Information: No Development Reported